Prostate-Reducing Agents

Posted by admin on May 10th, 2011 No Comments

Contents

Overview
Mechanism Of Action
NX-1207

Overview

One approach to reducing lower urinary tract symptoms resulting from benign prostatic hyperplasia is to reduce prostate hyperplasia, which limits the amount of smooth-muscle development and activity associated with dynamic benign prostatic hyperplasia as well as bladder outlet obstruction as a result of static benign prostatic hyperplasia. Development of this type of drug treatment is needed because it would relieve not only urinary symptoms but also the progression of benign prostatic hyperplasia. Nymox Pharmaceuticals is currently researching NX-1207, which has shown ability to reduce prostate size. The company has yet to release details about the exact mechanism of action, but clinical trials have focused on prostate size reduction and symptom relief.

Mechanism Of Action

Drug development databases suggest that NX-1207 has cytotoxic qualities that contribute to apoptosis within the prostate. However, the specific targets involved in the mechanism of action are unclear.

NX-1207

Nymox Pharmaceuticals is currently conducting Phase II clinical trials of its new oral drug, NX-1207, for the treatment of benign prostatic hyperplasia. So far, results from two major Phase I and I/II studies have been published. The Phase I study involved 20 men with benign prostatic hyperplasia who did not respond to alpha blockers and 5-ARIs. They were treated with NX-1207 for 30 days and exhibited a significant reduction in prostate size (p = 0.035) and an average reduction in AUASI of 6.87 points (p = 0.0352). In a follow-up Phase II study, patients continued their treatment for one year, by the end of which patients taking NX-1207 had an 8.8 point improvement in AUASI compared with the control group. A large-scale Phase II study is currently under way in the United States.

Benign Prostatic Hyperplasia:Emerging Therapies The ultimate goal of treatment of benign prostatic hyperplasia and its associated comorbidities is to alleviate clinical symptoms that affect quality of life, eliminate the need for surgery, and prevent chronic and acute urinary retention. The challenge to drug developers is to create agents ...
Hexokinase Inhibitors Overview In benign prostatic hyperplasia, hyperplasia of the prostate gland increases the number of smooth-muscle cells, and smooth-muscle tension causes bladder outlet obstruction leading to lower urinary tract symptoms . Drugs that reduce total prostate volume, either by slowing cell multiplication or inducing cell ...
Vitamin D3 Analogues Overview The active form of vitamin D3 is calcitriol. Initially, this steroid was shown to control bone metabolism and calcium equilibrium; it has the ability to induce hypercalcemia and hyperphosphatemia. Further research proved that calcitriol also moderates cell proliferation, differentiation, and apoptosis. Vitamin D3 ...
5-Alpha-Reductase Inhibitors Overview Because inhibition of the enzyme 5-alpha-reductase is known to reduce prostate size, patients with an enlarged prostate (greater than 40 g) are often prescribed a 5-alpha-reductase inhibitor (5-ARI). Along with alpha Mockers, 5-ARIs dominate the benign prostatic hyperplasia drug market. The agents currently ...
Finasteride The search for specific inhibitors of 5-alpha-reductase led to the discovery of finasteride (Merck's Proscar), which has been marketed in the United States and Europe since 1992 and is now the leading agent of this class. Merck licensed finasteride to Yamanouchi and Banyu, a ...

Posted in: Benign Prostatic Hyperplasia

Health and Prostate